Literature DB >> 33805795

The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials.

Carmine Izzo1,2, Monica Annunziata1,2, Giuseppe Melara1,2, Roberta Sciorio1,2, Marcello Dallio3, Mario Masarone1,2, Alessandro Federico3, Marcello Persico1,2.   

Abstract

Many studies have shown that resveratrol has a lot of therapeutic effects on liver disorders. Its administration can significantly increase the survival rate after liver transplantation, reduce fat deposition and ischemia-induced necrosis and apoptosis in Wistar rats. Resveratrol can provide Liver protection against chemical, cholestatic, and alcohol-mediated damage. It can improve glucose metabolism and lipid profile, reduce liver fibrosis, and steatosis. Additionally, it is capable of altering the fatty acid composition of the liver cells. Resveratrol may be a potential treatment option for the management of non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory, antioxidant, and calorie-restricting effects. There are also studies that have evaluated the effect of resveratrol on lipid and liver enzyme profiles among patients with metabolic syndrome (MetS) and related disorders. Based on the extent of liver disease worldwide and the need to find new treatment possibilities, this review critically examines current in vitro and in vivo preclinical studies and human clinical studies related to liver protection.

Entities:  

Keywords:  non-alcoholic fatty liver disease; nutraceutical; oxidative stress; resveratrol

Year:  2021        PMID: 33805795      PMCID: PMC7999728          DOI: 10.3390/nu13030933

Source DB:  PubMed          Journal:  Nutrients        ISSN: 2072-6643            Impact factor:   5.717


  196 in total

Review 1.  [Antioxidants and diabetes mellitus: review of the evidence].

Authors:  C Cuerda; L M Luengo; M A Valero; A Vidal; R Burgos; F L Calvo; C Martínez
Journal:  Nutr Hosp       Date:  2011 Jan-Feb       Impact factor: 1.057

Review 2.  Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.

Authors:  Stergios A Polyzos; Jannis Kountouras; Christos S Mantzoros
Journal:  Metabolism       Date:  2018-11-29       Impact factor: 8.694

3.  Effect of food on the pharmacokinetic profile of trans-resveratrol.

Authors:  M Vaz-da-Silva; A I Loureiro; A Falcao; T Nunes; J-F Rocha; C Fernandes-Lopes; E Soares; L Wright; L Almeida; P Soares-da-Silva
Journal:  Int J Clin Pharmacol Ther       Date:  2008-11       Impact factor: 1.366

4.  Resveratrol alleviate the injury of mice liver induced by cadmium sulfide nanoparticles.

Authors:  Chun-Yan Meng; Ya-Feng Han; Ying-Li Liu; Hong-Xia Gao; Yi-Yi Ren; Qing-Zeng Qian; Qian Wang; Qing-Zhao Li
Journal:  Kaohsiung J Med Sci       Date:  2019-03-26       Impact factor: 2.744

5.  Resveratrol amplifies profibrogenic effects of free fatty acids on human hepatic stellate cells.

Authors:  Lars P Bechmann; Denis Zahn; Robert K Gieseler; Christian D Fingas; Guido Marquitan; Christoph Jochum; Guido Gerken; Scott L Friedman; Ali Canbay
Journal:  Hepatol Res       Date:  2009-01-14       Impact factor: 4.288

6.  Apoptosis of lymphocytes in allograft in a rat liver transplantation model induced by resveratrol.

Authors:  Sheng-Li Wu; Liang Yu; Cheng-En Pan; Xing-Yuan Jiao; Yi Lv; Jian Fu; Ke-wei Meng
Journal:  Pharmacol Res       Date:  2006-03-03       Impact factor: 7.658

7.  Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet.

Authors:  Jiyun Ahn; Iljin Cho; Suna Kim; Daeyoung Kwon; Taeyoul Ha
Journal:  J Hepatol       Date:  2008-10-07       Impact factor: 25.083

8.  Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects.

Authors:  F K Knop; E Konings; S Timmers; P Schrauwen; J J Holst; E E Blaak
Journal:  Diabet Med       Date:  2013-06-07       Impact factor: 4.359

9.  Resveratrol prevents hepatic steatosis induced by hepatitis C virus core protein.

Authors:  Lina Jiang; Yu Gu; Jing Ye; Fang Liu; Yilin Zhao; Chao Wang; Yuqiao Xu; Xiangmei Cao; Liying Zhang; Wenpeng Dong; Fanfan Li; Jing Wang; Hui Wang; Qing Li
Journal:  Biotechnol Lett       Date:  2012-09-01       Impact factor: 2.461

View more
  5 in total

1.  Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease.

Authors:  Silvia Ferri; Bernardo Stefanini; Lorenzo Mulazzani; Margherita Alvisi; Francesco Tovoli; Simona Leoni; Luca Muratori; Tommaso Lotti; Alessandro Granito; Luigi Bolondi; Fabio Piscaglia
Journal:  Nutrients       Date:  2022-06-16       Impact factor: 6.706

Review 2.  Modulation of Oxidative Stress-Induced Senescence during Non-Alcoholic Fatty Liver Disease.

Authors:  Johanna Pedroza-Diaz; Johanna C Arroyave-Ospina; Sandra Serna Salas; Han Moshage
Journal:  Antioxidants (Basel)       Date:  2022-05-16

Review 3.  Targeting Oxidative Stress and Inflammation in Intervertebral Disc Degeneration: Therapeutic Perspectives of Phytochemicals.

Authors:  Liang Kang; Huaqing Zhang; Chongyu Jia; Renjie Zhang; Cailiang Shen
Journal:  Front Pharmacol       Date:  2022-07-12       Impact factor: 5.988

4.  Co-Treatment With Resveratrol and FGF1 Protects Against Acute Liver Toxicity After Doxorubicin Treatment via the AMPK/NRF2 Pathway.

Authors:  Xianchou Xu; Qingbo Liu; Jiahao Li; Mengjie Xiao; Ting Gao; Xiaohui Zhang; Guangping Lu; Jie Wang; Yuanfang Guo; Peinan Wen; Junlian Gu
Journal:  Front Pharmacol       Date:  2022-08-30       Impact factor: 5.988

5.  Integrated strategy of RNA-sequencing and network pharmacology for exploring the protective mechanism of Shen-Shi-Jiang-Zhuo formula in rat with non-alcoholic fatty liver disease.

Authors:  Zheng Xu; Fan-Wei Wu; Xuan Niu; Xiao-Peng Lu; Yan-Rong Li; Shu-Ting Zhang; Jun-Zhao Ou; Xue-Mei Wang
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.